Indoco Remedies' Baddi facility has achieved EU GMP certification, demonstrating adherence to global quality standards. In Q4, the company saw a significant 22% revenue increase to ₹476 crores, with improved EBITDA margin and a narrowed net loss compared to last year.

Indoco Remedies' Baddi Plant has been certified by the European Union (EU) for meeting Good Manufacturing Practice (GMP) standards, following an inspection by the German health authority. This recognition strengthens Indoco's global pharmaceutical reach.

ICICI Prudential Mutual Fund has made a significant investment in Indoco Remedies, acquiring approximately 683,544 shares priced at Rs. 198 each. This purchase underscores the fund's confidence in the company's potential.

Indoco Remedies has transferred its Ophthalmic business to Sunways India Pvt Ltd, as per an agreement signed on May 18, 2026. This sale encompasses operations in both India and various African countries.

Indoco Remedies' Baddi unit has successfully passed the Malta Medicines Authority audit, earning it the EU GMP certification. This recognition signifies that the facility maintains high standards of quality and regulatory compliance for pharmaceutical production.

Stylam Ind demonstrates robust operations, leading to a 13% share increase as Indoco Remedies transitions to EBITDA profit. Bharat Forge reaches an all-time high due to impressive results, anticipating a 25% revenue growth in the upcoming financial year.

Indoco Remedies has significantly reduced its Q4 net loss by approximately half, from ₹40 crore to ₹22 crore compared to last year. The company's revenue also saw a substantial increase of 22%, reaching ₹476 crore. Moreover, EBITDA improved and the margin was maintained at 10.6%.

Indoco Remedies narrowed its Q4 loss significantly, reporting a decline from 404 million rupees last year to 216 million rupees this year, demonstrating an improvement in the company's financial performance.

Indoco Remedies has agreed to sell its ophthalmic division to Sunways India for INR 110 crores, representing approximately 3.2% of their total revenue. The deal is anticipated to finalize within the next three months.

Indoco Remedies passes US FDA inspection at its Chhatrapati Sambhaji Nagar facility without any issues, indicating a successful pre-approval assessment and compliance with regulatory standards.

Indoco Remedies experiences a 3.86% share increase after passing the US FDA pre-approval inspection with no significant issues, trading at ₹209.95 per share. Despite an expanded Q3 net loss of ₹29.8 crore and a revenue uptick of 8.5%, EBITDA nearly tripled to ₹31.5 crore.

Indoco Remedies' testing facility successfully passed the FDA pre-approval inspection, demonstrating no areas for improvement. This is a significant milestone for the company in maintaining high-quality standards.

Indoco Remedies has successfully passed the recent US FDA inspection at their Aurangabad facility with no issues found, indicating a favorable position for exporting products to the U.S. market.